Ipamorelin
Ipamorelin is a selective ghrelin-receptor agonist studied for its ability to stimulate growth hormone release with minimal effect on cortisol or prolactin, making it a common reference compound in GH-axis research.
Part of KYIN Peptides' standard catalogue — see the product page for pricing, or the combined CJC-1295 + Ipamorelin Blend.
What Is Ipamorelin?
Ipamorelin came out of a medicinal-chemistry program at Novo Nordisk in Denmark during the late 1990s, aimed squarely at fixing a known problem with earlier growth-hormone-releasing peptides like GHRP-6 and hexarelin: those compounds reliably stimulated growth hormone release, but they also triggered unwanted spikes in cortisol, ACTH, and prolactin. Novo Nordisk's chemists identified the sequence responsible by systematically stripping down a related peptide series, eventually removing the central Ala-Trp dipeptide found in GHRP-1. The result, first published by Raun and colleagues in a 1998 paper in the European Journal of Endocrinology titled “Ipamorelin, the first selective growth hormone secretagogue,” was a pentapeptide that released growth hormone in research models at a potency comparable to GHRP-6, without the broader hormonal-axis disruption.
Research Focus
Ipamorelin's defining research property — selective ghrelin-receptor activity without broader hormonal-axis disruption — has made it a frequently used reference compound whenever a study needs to isolate growth-hormone-release effects specifically. It sits in KYIN's GHRH & Growth Hormone category alongside Tesamorelin and GHRP-6, and is most often studied paired with a GHRH analog like CJC-1295, as in our CJC-1295 + Ipamorelin Blend. See our GHRH & Growth Hormone research overview, or how it compares to CJC-1295 and Anamorelin as a non-peptide GHRP.
- Growth hormone release research
- Ghrelin receptor selectivity studies
- GH-axis pulsatility research
Clinical & Preclinical Trial Data
The foundational pharmacology paper (Raun et al., European Journal of Endocrinology, 1998) characterized ipamorelin's activity in rat pituitary cells and pigs, not in a human trial — establishing its selectivity (no significant ACTH or cortisol elevation, unlike earlier ghrelin-receptor agonists) but not efficacy or safety in humans. No completed human clinical trial of ipamorelin has been located.
Availability
Ipamorelin is part of KYIN Peptides' standard catalogue, sold both individually and combined with CJC-1295 — see the product page or the CJC-1295 + Ipamorelin Blend page for pricing, or contact us to order.
Ipamorelin questions
What is Ipamorelin?
Ipamorelin is a selective ghrelin-receptor agonist developed at Novo Nordisk in the late 1990s, engineered to stimulate growth hormone release with minimal effect on cortisol or prolactin — a selectivity problem earlier GHRP compounds like GHRP-6 did not solve.
Has Ipamorelin been tested in human trials?
No completed human clinical trial of ipamorelin has been located. The foundational pharmacology paper (Raun et al., European Journal of Endocrinology, 1998) characterized its activity in rat pituitary cells and pigs, establishing its receptor selectivity but not efficacy or safety in humans.
Does KYIN Peptides sell Ipamorelin?
Yes — Ipamorelin is part of our standard catalogue, both individually and combined with CJC-1295 in our CJC-1295 + Ipamorelin Blend. See the product pages for pricing.
Interested in Ipamorelin?
See pricing and order on the product page, or browse our other GHRH & growth hormone peptides.